Spinosad - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for spinosad and what is the scope of patent protection?
Spinosad
is the generic ingredient in one branded drug marketed by Cipher and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for spinosad. Two suppliers are listed for this compound.
Summary for spinosad
US Patents: | 1 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 9 |
Patent Applications: | 7,334 |
Drug Prices: | Drug price trends for spinosad |
What excipients (inactive ingredients) are in spinosad? | spinosad excipients list |
DailyMed Link: | spinosad at DailyMed |
Recent Clinical Trials for spinosad
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Concentrics Research | Phase 4 |
Medpace, Inc. | Phase 4 |
STATKING Clinical Services | Phase 4 |
Pharmacology for spinosad
Drug Class | Pediculicide |
US Patents and Regulatory Information for spinosad
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cipher | NATROBA | spinosad | SUSPENSION;TOPICAL | 022408-001 | Jan 18, 2011 | RX | Yes | Yes | 9,895,388 | ⤷ Subscribe | ⤷ Subscribe | ||||
Cipher | NATROBA | spinosad | SUSPENSION;TOPICAL | 022408-001 | Jan 18, 2011 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for spinosad
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cipher | NATROBA | spinosad | SUSPENSION;TOPICAL | 022408-001 | Jan 18, 2011 | 5,496,931 | ⤷ Subscribe |
Cipher | NATROBA | spinosad | SUSPENSION;TOPICAL | 022408-001 | Jan 18, 2011 | 7,030,095 | ⤷ Subscribe |
Cipher | NATROBA | spinosad | SUSPENSION;TOPICAL | 022408-001 | Jan 18, 2011 | 6,342,482 | ⤷ Subscribe |
Cipher | NATROBA | spinosad | SUSPENSION;TOPICAL | 022408-001 | Jan 18, 2011 | 6,063,771 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for spinosad
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Elanco GmbH | Comfortis | spinosad | EMEA/V/C/002233 Treatment and prevention of flea infestations (Ctenocephalides felis).The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). |
Withdrawn | no | no | no | 2011-02-11 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
Spinosad Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.